<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04757051</url>
  </required_header>
  <id_info>
    <org_study_id>BEN-PMCF-DE-2020</org_study_id>
    <nct_id>NCT04757051</nct_id>
  </id_info>
  <brief_title>Real-life Use of BENART TM in Patients With Symptomatic Knee Osteoarthritis</brief_title>
  <official_title>Real-life Use of BENART TM in Patients With Symptomatic Knee Osteoarthritis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>TRB Chemedica AG</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>TRB Chemedica AG</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      PMCF study to assess the effectiveness and safety of BENART in the treatment of symptomatic&#xD;
      knee OA in a real-life clinical setting when used according to the instructions for use.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">March 11, 2021</start_date>
  <completion_date type="Anticipated">January 2022</completion_date>
  <primary_completion_date type="Anticipated">January 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Change of subjective therapy evaluation (KOOS questionnaire) compared to baseline</measure>
    <time_frame>week 1, week 12, week 24, week 36</time_frame>
    <description>Knee injury and Osteoarthritis Outcome Score (KOOS) to assess pain, other symptoms, activities of daily living (ADL), function in sport and recreation (Sport/Rec) and knee-related Quality of Life (QoL) on a 5-point Likert scale</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change of pain intensity compared to baseline (visual analogue scale, VAS)</measure>
    <time_frame>week 1, week 12, week 24, week 36</time_frame>
    <description>Evaluation of pain intensity by the patient on a 10 cm VAS-slider. 10 cm equals the worst pain.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change of patient's global assessment (overall impression of clinical OA severity on a numerical rating scale from 0 to 10)</measure>
    <time_frame>week 1, week 12, week 24, week 36</time_frame>
    <description>The change of overall subjective symptom severity evaluation on a scale from 0 (very good condition) to 10 (very poor condition).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change of clinical global impression (overall impression of clinical OA severity of the investigator on a numerical rating scale from 0 to 10)</measure>
    <time_frame>week 1, week 12, week 24, week 36</time_frame>
    <description>The change of clinical global Impression on a scale from 0 (very good condition) to 10 (very poor condition).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Responder rate according to OMERACT-OARSI criteria</measure>
    <time_frame>week 24</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of treatment-emergent Adverse Events</measure>
    <time_frame>Up to week 36</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Satisfaction scale (subjective satisfaction of patient and investigator with the treatment on a 5 Point likert scale)</measure>
    <time_frame>week 1, week 12, week 24, week 36</time_frame>
    <description>Subjective satisfaction on a scale from 1 (very satisfied) to 5 (very unsatisfied)</description>
  </primary_outcome>
  <enrollment type="Actual">50</enrollment>
  <condition>Knee Osteoarthritis</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Patients between 18 and 99 years with knee osteoarthitis and a recommendation for treatment&#xD;
        with BENART TM.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  male or female aged between 18 and 99 years&#xD;
&#xD;
          -  diagnosis of symptomatic knee OA: Kellgren &amp; Lawrence grade II/III&#xD;
&#xD;
          -  physician's recommendation to use BENART TM prior to recruitment&#xD;
&#xD;
          -  signed informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  known allergy or hypersensitivity to any of the BENART TM components&#xD;
&#xD;
          -  infection or skin disease at or around the injection site&#xD;
&#xD;
          -  severe Inflammation, synovitis, or arthritis of the knee joint and/or any other signs&#xD;
             of inflammation (e.g. pain causing nocturnal awakenings, knee heat,...)&#xD;
&#xD;
          -  history of autoimmune and crystal diseases (e.g. gout, pseudogout, hereditary&#xD;
             hemochromatosis, ...)&#xD;
&#xD;
          -  evidence of lymphatic or venous stasis or serious blood disorders&#xD;
&#xD;
          -  known pregnancy or breast feeding&#xD;
&#xD;
          -  significant joint effusion (confirmed by objective clinical signs and/or ultrasound&#xD;
             and/or puncture)&#xD;
&#xD;
          -  individuals who are unable to fully understand all aspects of the study that are&#xD;
             relevant to the decision to participate, or who could be manipulated or unduly&#xD;
             influenced as a result of a compromised position, expectation of benefits or fear of&#xD;
             retaliatory response (including persons needing legally designated representatives,&#xD;
             illiterate persons or persons with insufficient knowledge of local language)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>Dr. med. Eichhorn</last_name>
    <role>Principal Investigator</role>
    <affiliation>Praxiszentrum Elisengalerie</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Praxiszentrum Elisengalerie</name>
      <address>
        <city>Aachen</city>
        <zip>52062</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>February 11, 2021</study_first_submitted>
  <study_first_submitted_qc>February 11, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">February 16, 2021</study_first_posted>
  <last_update_submitted>October 7, 2021</last_update_submitted>
  <last_update_submitted_qc>October 7, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoarthritis</mesh_term>
    <mesh_term>Osteoarthritis, Knee</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

